IL6R and inflammatory bowel disease: Patients with chronic immune‐mediated inflammatory diseases [IMIDs, e.g. rheumatoid arthritis (RA) or inflammatory bowel diseases (IBD)] who are treated with cytokine inhibitors (e.g. TNF antagonists, anti‐IL6R therapy) do not seem to be at an automatically increased risk of developing severe COVID‐19 [63].